Diverse Biotech

Diverse Biotech is developing a novel drug conjugate platform that links synthetic cannabinoids (e.g., CBD) to therapeutic payloads to create targeted cancer therapies with improved efficacy and safety. The company's lead focus appears to be on glioblastoma and other cancers, leveraging cannabinoids to enhance blood-brain barrier penetration and localize drug delivery. As a private, pre-revenue company, Diverse Biotech is actively seeking strategic partners and investors to advance its preclinical programs into clinical development. Its leadership combines scientific expertise in chemistry and oncology with business acumen from the Wharton School.

Proprietary Conjugate Synthesis Platform that links synthetic cannabinoids (e.g., CBD) to therapeutic drug payloads to enable targeted delivery, enhance blood-brain barrier penetration, and improve therapeutic index by localizing drug release at the site of action.

Operates in the highly competitive targeted oncology therapy space, competing against large pharma and biotech companies developing antibody-drug conjugates (ADCs), small molecule inhibitors, and other novel modalities. Its differentiation lies in the unique use of synthetic cannabinoids as a targeting/delivery mechanism for enhanced brain penetration.